Luteolin and abyssinone II as potential inhibitors of SARS-CoV-2: an in silico molecular modeling approach in battling the COVID-19 outbreak

Bulletin of the National Research Centre - 2021
Mohammad Mahfuz Ali Khan Shawan1, Sajal Kumar Halder1, Md. Ashraful Hasan1
1Department of Biochemistry and Molecular Biology, Jahangirnagar University, Savar, Dhaka, 1342, Bangladesh

Tóm tắt

Abstract Background At present, the entire world is in a war against COVID-19 pandemic which has gradually led us toward a more compromised “new normal” life. SARS-CoV-2, the pathogenic microorganism liable for the recent COVID-19 outbreak, is extremely contagious in nature resulting in an unusual number of infections and death globally. The lack of clinically proven therapeutic intervention for COVID-19 has dragged the world’s healthcare system into the biggest challenge. Therefore, development of an efficient treatment scheme is now in great demand. Screening of different biologically active plant-based natural compounds could be a useful strategy for combating this pandemic. In the present research, a collection of 43 flavonoids of 7 different classes with previously recorded antiviral activity was evaluated via computational and bioinformatics tools for their impeding capacity against SARS-CoV-2. In silico drug likeness, pharmacophore and Absorption, Distribution, Metabolism, Excretion and Toxicity (ADMET) profile analysis of the finest ligands were carried out using DataWarrior, DruLiTo and admetSAR programs, respectively. Molecular docking was executed by AutoDock Vina, while molecular dynamics simulation of the target protein–ligand bound complexes was done using nanoscalable molecular dynamics and visual molecular dynamics software package. Finally, the molecular target analysis of the selected ligands within Homo sapiens was conducted with SwissTargetPredcition web server. Results Out of the forty-three flavonoids, luteolin and abyssinone II were found to develop successful docked complex within the binding sites of target proteins in terms of lowest binding free energy and inhibition constant. The root mean square deviation and root mean square fluctuation values of the docked complex displayed stable interaction and efficient binding between the ligands and target proteins. Both of the flavonoids were found to be safe for human use and possessed good drug likeness properties and target accuracy. Conclusions Conclusively, the current study proposes that luteolin and abyssinone II might act as potential therapeutic candidates for SARS-CoV-2 infection. In vivo and in vitro experiments, however, should be taken under consideration to determine the efficiency and to demonstrate the mechanism of action.

Từ khóa


Tài liệu tham khảo

Daina A, Michielin O, Zoete V (2019) SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules. Nucleic Acids Res 47(W1):W357–W364

Devaux C, Rolain J, Colson P, Raoult D (2020) New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents 55(5):105938

Du L, He Y, Zhou Y, Liu S, Zheng B, Jiang S (2009) The spike protein of SARS-CoV-a target for vaccine and therapeutic development. Nat Rev Microbiol 7(3):226–236

Elmezayen A, Al-Obaidi A, Şahin A, Yelekçi K (2020) Drug repurposing for coronavirus (COVID-19): in silico screening of known drugs against coronavirus 3CL hydrolase and protease enzymes. J Biomol Struct Dyn 2020:1–13

Enayatkhani M, Hasaniazad M, Faezi S, Gouklani H, Davoodian P, Ahmadi N et al (2020) Reverse vaccinology approach to design a novel multi-epitope vaccine candidate against COVID-19: an in silico study. J Biomol Struct Dyn 2020:1–16

Enmozhi S, Raja K, Sebastine I, Joseph J (2020) Andrographolide as a potential inhibitor of SARS-CoV-2 main protease: an in silico approach. J Biomol Struct Dyn 2020:1–7

Ghersi D, Sanchez R (2009) Improving accuracy and efficiency of blind protein-ligand docking by focusing on predicted binding sites. Proteins 74(2):417–424

Guan L, Yang H, Cai Y et al (2018) ADMET-score—a comprehensive scoring function for evaluation of chemical drug-likeness. Medchemcomm 10(1):148–157

Guan W, Ni Z, Hu Y, Liang W, Ou C, He J et al (2020) Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 382(18):1708–1720

Guo Y, Cao Q, Hong Z, Tan Y, Chen S, Jin H et al (2020) The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak—an update on the status. Mil Med Res 7(1):11

Gurung A, Ali M, Lee J, Farah M, Al-Anazi K (2020) Unravelling lead antiviral phytochemicals for the inhibition of SARS-CoV-2 Mpro enzyme through in silico approach. Life Sci 255:117831

Hanwell M, Curtis D, Lonie D, Vandermeersch T, Zurek E, Hutchison G (2012) Avogadro: an advanced semantic chemical editor, visualization, and analysis platform. J Cheminform 4(1):17

Hilgenfeld R (2014) From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design. FEBS J 281(18):4085–4096

Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S et al (2020) SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181(2):271–280

Humphrey W, Dalke A, Schulten K (1996) VMD: visual molecular dynamics. J Mol Graph 14(1):33–38

Jo S, Kim T, Iyer VG, Im W (2008) CHARMM-GUI: a web-based graphical user interface for CHARMM. J Comput Chem 29(11):1859–1865

Johansson M, Zoete V, Michielin O, Guex N (2012) Defining and searching for structural motifs using DeepView/Swiss-PdbViewer. BMC Bioinform 13(1):173

Joshi T, Joshi T, Sharma P, Mathpal S, Pundir H, Bhatt V et al (2020) In silico screening of natural compounds against COVID-19 by targeting Mpro and ACE2 using molecular docking. Eur Rev Med Pharmacol Sci 24(8):4529–4536

Kitchen D, Decornez H, Furr J, Bajorath J (2004) Docking and scoring in virtual screening for drug discovery: methods and applications. Nat Rev Drug Discov 3(11):935–949

Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B et al (2005) A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury. Nat Med 11(8):875–879

Liu C, Zhou Q, Li Y, Garner L, Watkins S, Carter L et al (2020) Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases. ACS Cent Sci 6(3):315–331

MacKerell AD, Bashford D, Bellott M et al (1998) All-atom empirical potential for molecular modeling and dynamics studies of proteins. J Phys Chem B 102(18):3586–3616

Mehta N, Mazer-Amirshahi M, Alkindi N, Pourmand A (2020) Pharmacotherapy in COVID-19; a narrative review for emergency providers. Am J Emerg Med 38(7):1488–1493

Meng X, Zhang H, Mezei M, Cui M (2011) Molecular docking: a powerful approach for structure-based drug discovery. Curr Comput Aided Drug Des 7(2):146–157

Meyerowitz EA, Vannier AGL, Friesen MGN et al (2020) Rethinking the role of hydroxychloroquine in the treatment of COVID-19. FASEB J 34(5):6027–6037

Mohammadi Pour P, Fakhri S, Asgary S, Farzaei M, Echeverría J (2019) The signaling pathways, and therapeutic targets of antiviral agents: focusing on the antiviral approaches and clinical perspectives of anthocyanins in the management of viral diseases. Front Pharmacol 10:1207

Molyneux R, Lee S, Gardner D, Panter K, James L (2007) Phytochemicals: the good, the bad and the ugly? Phytochemistry 68(22–24):2973–2985

Newman D, Cragg G (2007) Natural products as sources of new drugs over the last 25 years. J Nat Prod 70(3):461–477

Nosrati M, Hajizade A, Nazarian S, Amani J, Namvar Vansofla A, Tarverdizadeh Y (2019) Designing a multi-epitope vaccine for cross-protection against Shigella spp: an immunoinformatics and structural vaccinology study. Mol Immunol 116:106–116

Notka F, Meier G, Wagner R (2004) Concerted inhibitory activities of on HIV replication in vitro and ex vivo. Antiviral Res 64(2):93–102

Pettersen E, Goddard T, Huang C, Couch G, Greenblatt D, Meng E et al (2004) UCSF Chimera- a visualization system for exploratory research and analysis. J Comput Chem 25(13):1605–1612

Phillips JC, Braun R, Wang W et al (2005) Scalable molecular dynamics with NAMD. J Comput Chem 26(16):1781–1802

Rahman A, Ali MT, Shawan MM, Sarwar MG, Khan MA, Halim MA (2016) Halogen-directed drug design for Alzheimer’s disease: a combined density functional and molecular docking study. Springerplus 5(1):1346

Ramírez D, Caballero J (2018) Is it reliable to take the molecular docking top scoring position as the best solution without considering available structural data? Molecules 23(5):1038

Rasool N, Ashraf A, Waseem M, Hussain W, Mahmood S (2018) Computational exploration of antiviral activity of phytochemicals against NS2B/NS3 proteases from dengue virus. Turk J Biochem 44(3):261–277

Rehman S, Ashfaq U, Riaz S, Javed T, Riazuddin S (2011) Antiviral activity of Acacia nilotica against Hepatitis C Virus in liver infected cells. Virol J 8(1):220

Rut W, Lv Z, Zmudzinski M, Patchett S, Nayak D, Snipas S et al (2020) Activity profiling and structures of inhibitor-bound SARS-CoV-2-PLpro protease provides a framework for anti-COVID-19 drug design. bioRxiv 6(42). https://doi.org/10.1101/2020.04.29.068890.

Samofalova D, Karpov P, Raevsky A, Blume Y (2017) Protein phosphatases potentially associated with regulation of microtubules, their spatial structure reconstruction and analysis. Cell Biol Int 43(9):1081–1090

Shah B, Modi P, Sagar S (2020) In silico studies on therapeutic agents for COVID-19: drug repurposing approach. Life Sci 252:117652

Snøve O Jr, Holen T (2004) Many commonly used siRNAs risk off-target activity. Biochem Biophys Res Commun 319(1):256–263

Song JJ, Smith SK, Hannon GJ, Joshua-Tor L (2004) Crystal structure of Argonaute and its implications for RISC slicer activity. Science 305(5689):1434–1437

Towler P, Staker B, Prasad S, Menon S, Tang J, Parsons T et al (2004) ACE2 X-ray structures reveal a large hinge-bending motion important for inhibitor binding and catalysis. J Biol Chem 279(17):17996–18007

Umar A, Uzairu A, Shallangwa G, Uba S (2020) Docking-based strategy to design novel flavone-based arylamides as potent V600E-BRAF inhibitors with prediction of their drug-likeness and ADMET properties. Bull Natl Res Cent 44(1):1–11

Uno Y (2020) Camostat mesilate therapy for COVID-19. Intern Emerg Med 15(8):1577–1578

World Health Organization (WHO) (2020) Coronavirus disease (COVID-19) pandemic. https://www.who.int/emergencies/diseases/novel-coronavirus-2019. Accessed 13 Nov 2020

Zakaryan H, Arabyan E, Oo A, Zandi K (2017) Flavonoids: promising natural compounds against viral infections. Arch Virol 162(9):2539–2551

Thông tin
Thông tin xuất bản

Bulletin of the National Research Centre

Thông tin tác giả